SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 10^th, the 2024 International Convention on Pharmaceutical Ingredients and Intermediates Europe Exhibition (CPHI Milan 2024), one of the largest and most influential pharmaceutical industry events globally, concluded successfully at the Milan International Exhibition Center in Italy. Kexing Biopharm, a Chinese high-quality biopharmaceutical outbound platform, made an appearance at the event and garnered widespread attention with its diverse product line and cutting-edge innovative strength.

Led by Kexing Biopharm General Manager Mr. Zhao Yanqing, Kexing Biopharm showcased an impressive array of products at the event, covering several therapeutic areas including oncology, autoimmunity, and metabolism. The showcased products included human erythropoietin (EPO), human granulocyte colony-stimulating factor (GC), combined Clostridium Butyricum and Bifidobacterium, live, albumin-bound paclitaxel (Apexelsin^®), bevacizumab, infliximab, adalimumab, trastuzumab, liraglutide, and palbociclib etc.

It is worth mentioning that Kexing Biopharm held a launch ceremony for Protein bound Paclitaxel (Apexelsin®) in the European Union during the exhibition. The company has set a new production line according to the EU pharmaceutical GMP standards for Apexelsin® and has simultaneously carried out registration work in multiple countries. The product received the EU pharmaceutical GMP certificate in May this year and was approved for marketing in the EU at the end of July. It has begun shipping in August. Apexelsin® has officially entered the European pharmaceutical market, showcasing the company's overseas expansion capabilities in the anti-cancer field. This is also a pivotal step in gradually enhancing its commercial presence abroad and progressively advancing the "globalization" strategy.

In addition, the partner in the Middle East, Saudi Arabia, signed on site at the booth, marking a further deepening cooperation between the two sides. The representative of the cooperation party said that in the future, both sides will continue to promote the cooperation on more products and work together to advance the development of pharmaceuticals in the Middle East.

Kexing Biopharm will continue to adhere to the development vision of "innovation plus internationalization" and actively license in high-quality blockbuster drugs, and strengthen communication and cooperation with global partners and jointly promote innovation and development in the pharmaceutical industry.

View original content:https://www.prnewswire.co.uk/news-releases/kexing-biopharm-made-its-appearance-at-cphi-milan-2024-launch-ceremony-for-apexelsin--in-eu-market-successfully-done-302279113.html

Tags

More Like This

Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval

Kexing Biopharm Attended CPHI Worldwide 2023

Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026

2024 International Pharmaceutical Cooperation High-End Forum Kexing Biopharm's Series of Globalization Activities (China) Successfully Concluded

Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025

Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion

Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

CPHI & PMEC China Sees Surge in International Attendance as Global Pharma Trade Outlook Strengthens